Coronavirus

Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID

Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patients Following Infection with…

3 years ago

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

Clinical Trial Shows Substantially Increased Bioavailability with Food and a Clean Safety and Pharmacologic ProfileCALGARY, Alberta, Aug. 22, 2022 (GLOBE…

3 years ago

Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing

Provista begins validation preparations for blood-based IgM/IgG MonkeyPox LDTCompany to release its Q2/2022 10Q quarterly report at 4:05 pm ET…

3 years ago

Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients

STI-1558, an oral SARS-CoV-2 main protease (Mpro) inhibitor, which can block viral replication, is specifically designed as a standalone treatment…

3 years ago

Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID

New York, NY, and Tel Aviv, ISRAEL, Aug. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive…

3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company…

3 years ago

Favor Teams Up with imaware to Offer Discrete At-Home STI Tests to Women and People Who Menstruate

Powered by imaware’s advanced testing capability, STI kit is most comprehensive on the marketAUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE)…

3 years ago

Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an…

3 years ago